secwatch.observer — SEC 8-K summary
======================================

Issuer:     Longeveron Inc. (LGVN)
CIK:        0001721484
Form:       8-K
Filed at:   2023-02-28T23:59:59+00:00
Accession:  0001213900-23-015114
Event type: leadership
Sentiment:  neutral
Materiality: 0.60
Item codes: 5.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Longeveron appoints Wa'el Hashad as CEO effective March 1, 2023
---------------------------------------------------------------

- Wa'el Hashad named CEO, effective March 1, 2023; joins Board of Directors.
- Hashad previously President & CEO of Avanir Pharmaceuticals (2017-2023).
- Interim CEO Chris Min, M.D., Ph.D., returns to role as Chief Medical Officer.
- Compensation: $530k annual salary, up to 70% bonus, 50,000 RSU signing bonus.
- Hashad brings 35+ years experience at Amgen, Boehringer Ingelheim, Eli Lilly.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1721484/000121390023015114/0001213900-23-015114-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1721484/000121390023015114/ea174406-8k_longeveron.htm
  HTML page:      https://secwatch.observer/filing/0001213900-23-015114

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer